Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Randomized Study of Cetuximab +/- Brivanib Alaninate (BMS-582664) in Patients With K-RAS Wild Type Tumors Previously Treated With Combination Chemotherapy for Metastatic Colorectal Carcinoma

Trial Profile

A Phase III Randomized Study of Cetuximab +/- Brivanib Alaninate (BMS-582664) in Patients With K-RAS Wild Type Tumors Previously Treated With Combination Chemotherapy for Metastatic Colorectal Carcinoma

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jan 2018

At a glance

  • Drugs Brivanib alaninate (Primary) ; Cetuximab
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 20 Jan 2018 Results assessing the association of FCGR2A and FCGR3A polymorphisms with outcomes in cetuximab treated patients (n=592) presented at the 2018 Gastrointestinal Cancers Symposium
    • 06 Jun 2017 Data from this trial was used to perform population pharmacokinetic (pop-pK) analysis of Cetuximab in patients with KRAS WT metastatic colorectal cancer , results (n=703) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top